다우존스 지수

실시간 차트, 분석 도구 및 가격을 받으려면 등록하세요.

등록

ABBV

AbbVie (ABBV)

AbbVie Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NYSE:ABBV

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/04/26	20:47	IH Market News	U.S. Futures Climb in Pre-Market Trading Amid Tech Gains and Upcoming Inflation Data	NYSE:ABBV	AbbVie Inc
2024/04/26	20:35	PR Newswire (US)	AbbVie Reports First-Quarter 2024 Financial Results	NYSE:ABBV	AbbVie Inc
2024/04/25	21:00	PR Newswire (US)	New Data Show RINVOQ® (upadacitinib) Demonstrated Superiority Versus DUPIXENT® (dupilumab) Across Primary and All Secondary Endpoints in an Open-Label Head-to-Head Atopic Dermatitis Study	NYSE:ABBV	AbbVie Inc
2024/04/23	21:00	PR Newswire (US)	Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands	NYSE:ABBV	AbbVie Inc
2024/04/18	21:31	PR Newswire (US)	Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis	NYSE:ABBV	AbbVie Inc
2024/04/12	20:30	PR Newswire (US)	AbbVie Announces Late-Breaking Data at AAN Supporting Long-Term Safety and Efficacy of Atogepant (QULIPTA®) for Preventive Treatment of Migraine	NYSE:ABBV	AbbVie Inc
2024/04/09	21:00	PR Newswire (US)	SkinMedica® Empowers Clear Skin Confidence with a New, Modern Approach to Acne	NYSE:ABBV	AbbVie Inc
2024/04/04	21:00	PR Newswire (US)	AbbVie to Host First-Quarter 2024 Earnings Conference Call	NYSE:ABBV	AbbVie Inc
2024/04/03	21:30	PR Newswire (US)	Allergan Aesthetics Announces the Return of CoolMonth with CoolSculpting®	NYSE:ABBV	AbbVie Inc
2024/04/01	20:50	GlobeNewswire Inc.	NEXGEL Reports Full Year 2023 Revenue of $4.1 Million, an Increase of 99.7% Year-Over-Year	NYSE:ABBV	AbbVie Inc
2024/03/26	20:20	IH Market News	Super Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest News	NYSE:ABBV	AbbVie Inc
2024/03/26	00:00	PR Newswire (US)	Allergan Aesthetics Launches "Moving the Needle on Ethics" to Elevate the Conversation Around Ethics in Aesthetics	NYSE:ABBV	AbbVie Inc
2024/03/25	21:31	PR Newswire (US)	AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases	NYSE:ABBV	AbbVie Inc
2024/03/25	21:30	GlobeNewswire Inc.	AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases	NYSE:ABBV	AbbVie Inc
2024/03/23	04:02	PR Newswire (US)	U.S. Food and Drug Administration (FDA) Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients	NYSE:ABBV	AbbVie Inc
2024/03/21	21:00	PR Newswire (US)	ALLERGAN AESTHETICS CONTINUES TO CHAMPION INDIVIDUALITY, DRIVE INNOVATION AND LEAD WITH INTEGRITY AS IT HOSTS EXPERT LED SYMPOSIA AT AMWC 2024	NYSE:ABBV	AbbVie Inc
2024/03/07	22:00	PR Newswire (US)	AbbVie to Present at the Barclays 26th Annual Global Healthcare Conference	NYSE:ABBV	AbbVie Inc
2024/03/06	22:03	PR Newswire (US)	AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios	NYSE:ABBV	AbbVie Inc
2024/03/06	07:30	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ABBV	AbbVie Inc
2024/03/06	02:09	PR Newswire (Canada)	Dragonfly a reçu un paiement d'étape à la suite de la prise de dose du premier patient à l'essai clinique de phase 1 d'AbbVie évaluant le DF4101/ABBV-303	NYSE:ABBV	AbbVie Inc
2024/03/05	22:00	PR Newswire (US)	JUVÉDERM® VOLUMA® XC For Temple Hollows Receives U.S. FDA Approval	NYSE:ABBV	AbbVie Inc
2024/03/05	21:00	PR Newswire (US)	Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303	NYSE:ABBV	AbbVie Inc
2024/03/05	21:00	PR Newswire (Canada)	Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303	NYSE:ABBV	AbbVie Inc
2024/03/05	21:00	PR Newswire (US)	Dragonfly has Received Milestone Payment Following Dosing of First Patient in AbbVie Phase 1 Clinical Trial Evaluating DF4101/ABBV-303	NYSE:ABBV	AbbVie Inc
2024/03/02	09:53	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:ABBV	AbbVie Inc
2024/03/02	07:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ABBV	AbbVie Inc
2024/03/02	07:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ABBV	AbbVie Inc
2024/03/02	07:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ABBV	AbbVie Inc
2024/03/02	07:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ABBV	AbbVie Inc
2024/03/02	07:50	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:ABBV	AbbVie Inc

검색 관련기사 보기:NYSE:ABBV

1 2 3 4 5 6 7 8 9 10 다음 >>

Gold vs US Dollar

JP Morgan Chase

US Dollar vs Sterling

American Express

US Dollar vs Yen

Energy Select Sector SPDR

Verizon Communications

Delayed Upgrade Clock

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관